Smith Miriam J, Isidor Bertand, Beetz Christian, Williams Simon G, Bhaskar Sanjeev S, Richer Wilfrid, O'Sullivan James, Anderson Beverly, Daly Sarah B, Urquhart Jill E, Fryer Alan, Rustad Cecilie F, Mills Samantha J, Samii Amir, du Plessis Daniel, Halliday Dorothy, Barbarot Sebastien, Bourdeaut Franck, Newman William G, Evans D Gareth
From the Manchester Centre for Genomic Medicine (M.J.S., W.G.N., D.G.E.) and University of Manchester Biomedical Imaging Institute (S.J.M.), Manchester Academic Health Sciences Centre, and Centre for Imaging Sciences (S.J.M.), University of Manchester, UK; Service de Dermatologie (S.B.) and Service de Genetique Medicale (B.I.), CHU Nantes, France; Institut für Klinische Chemie und Laboratoriumsdiagnostik Universitätsklinikum Jena (C.B.), Germany; Centre for Genomic Medicine (S.G.W., S.S.B., J.O., B.A., S.B.D., J.E.U., W.G.N., D.G.E.), St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, UK; INSERM U830 (W.R., F.B.), Laboratoire de Genetique et Biologie des Cancers, Paris, France; Department of Clinical Genetics (A.F.), Alder Hey Children's Hospital, Liverpool, UK; Department of Medical Genetics (C.F.R.), Oslo University Hospital, Norway; International Neuroscience Institute (A.S.), Hannover, Germany; Department of Cellular Pathology and Greater Manchester Neurosciences Centre (D.d.P.), Salford Royal Hospitals NHS Foundation Trust; Department of Clinical Genetics (D.H.), Oxford Radcliffe Hospitals NHS Trust, UK; and Institut Curie (F.B.), SIRIC and Departement d'Oncologie Pediatrique d'Adolescents et Jeunes Adultes, Paris, France.
Neurology. 2015 Jan 13;84(2):141-7. doi: 10.1212/WNL.0000000000001129. Epub 2014 Dec 5.
We aimed to determine the proportion of individuals in our schwannomatosis cohort whose disease is associated with an LZTR1 mutation.
We used exome sequencing, Sanger sequencing, and copy number analysis to screen 65 unrelated individuals with schwannomatosis who were negative for a germline NF2 or SMARCB1 mutation. We also screened samples from 39 patients with a unilateral vestibular schwannoma (UVS), plus at least one other schwannoma, but who did not have an identifiable germline or mosaic NF2 mutation.
We identified germline LZTR1 mutations in 6 of 16 patients (37.5%) with schwannomatosis who had at least one affected relative, 11 of 49 (22%) sporadic patients, and 2 of 39 patients with UVS in our cohort. Three germline mutation-positive patients in total had developed a UVS. Mosaicism was excluded in 3 patients without germline mutation in NF2, SMARCB1, or LZTR1 by mutation screening in 2 tumors from each.
Our data confirm the relationship between mutations in LZTR1 and schwannomatosis. They indicate that germline mutations in LZTR1 confer an increased risk of vestibular schwannoma, providing further overlap with NF2, and that further causative genes for schwannomatosis remain to be identified.
我们旨在确定在我们的神经鞘瘤病队列中,其疾病与LZTR1突变相关的个体比例。
我们使用外显子组测序、桑格测序和拷贝数分析,对65名无亲缘关系的神经鞘瘤病患者进行筛查,这些患者的种系NF2或SMARCB1突变检测为阴性。我们还对39名单侧前庭神经鞘瘤(UVS)患者的样本进行了筛查,这些患者至少还有一个其他神经鞘瘤,但没有可识别的种系或镶嵌性NF2突变。
在我们的队列中,16名至少有一名患病亲属的神经鞘瘤病患者中有6名(37.5%)、49名散发性患者中有11名(22%)以及39名UVS患者中有2名检测到种系LZTR1突变。总共有3名种系突变阳性患者发生了UVS。通过对每个患者的2个肿瘤进行突变筛查,排除了3名在NF2、SMARCB1或LZTR1中无种系突变的患者存在镶嵌现象。
我们的数据证实了LZTR1突变与神经鞘瘤病之间的关系。这些数据表明,LZTR1种系突变会增加前庭神经鞘瘤的发病风险,这进一步与NF2存在重叠,并且神经鞘瘤病的其他致病基因仍有待确定。